Vaccine Contracts
Moderna’s COVID-19 vaccine uses messenger RNA (mRNA) technology. Unlike traditional vaccines, which often use weakened or inactivated virus, mRNA vaccines work by instructing cells to produce a spike protein that triggers an immune response. In addition, Moderna offers a RSV vaccine, mRESVIA, to protect adults aged 60 or older against lower respiratory tract disease caused by respiratory syncytial virus.
The Align Healthcare Partners & Moderna agreement provides Members with on-invoice savings for both the COVID-19 and RSV vaccine.
Resources:
Ordering Methods
Coding for Reimbursement
CSL Seqirus is a global leader in vaccine innovation, particularly in the field of influenza vaccines. Their portfolio includes a range of flu vaccines designed to protect individuals from seasonal influenza, including cell-based flu vaccines for those with egg allergies and adjuvanted vaccines like Fluad to boost immunity in older adults.
The Align Healthcare Partners & CSL Seqirus agreement provides members with on-invoice savings for Influenza vaccines.
Afluria: A quadrivalent influenza vaccine that helps prevent seasonal flu caused by four strains of the influenza virus. Approved for individuals 6 months of age and older.
Fluad: An adjuvanted influenza vaccine for individuals aged 65 and older. It combines an inactivated flu virus with an adjuvant, helping to enhance the immune response in older adults, who may have a weaker immune system.
Flucelvax: A cell-based influenza vaccine used to protect individuals aged 4 years and older. Unlike traditional egg-based vaccines, Flucelvax is produced using cultured animal cells, offering a safe option for those with egg allergies.
Resources:
Ordering Methods